Large-scale testing (Phase 3)UnknownNCT05910970
What this trial is testing
Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation
Who this might be right for
Hepatocellular CarcinomaRecurrenceImmune Checkpoint Inhibitor
Guangxi Medical University 200